株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のバイオバンキング市場の調査と分析

Global Bio-Banking market Research and Forecast 2018-2023

発行 Orion Market Research Pvt Ltd 商品コード 637941
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=111.19円で換算しております。
Back to Top
世界のバイオバンキング市場の調査と分析 Global Bio-Banking market Research and Forecast 2018-2023
出版日: 2018年04月18日 ページ情報: 英文
概要

当レポートでは、世界のバイオバンキング市場について調査分析を行い、市場概要、市場動向、競合状況などについて考察するとともに、地域別に市場を分析、企業プロファイルなどについて包括的に分析し、まとめています。

第1章 レポートのサマリー

  • 調査方法とツール
  • 市場概要

第2章 市場概要と考察

  • 定義
  • アナリストによる考察と現在の市場動向
  • 規制
  • パイプライン分析

第3章 市場決定因子

  • 市場促進因子
  • 市場抑制因子
  • 市場機会

第4章 市場セグメンテーション

  • 世界のバイオバンキング市場:サンプル種類別
  • 世界のバイオバンキング市場:用途別

第5章 競合状況

  • 主要戦略
  • 主要企業分析

第6章 地域別分析

  • 北米
  • 欧州
  • アジア太平洋地域
  • 世界のその他の諸国

第7章 企業プロファイル

  • ABBOTT LABORATORIES INC
  • AFFYMETRIX, INC
  • ASTERAND PLC
  • ASTRAZENECA LTD
  • BAYER SCHERING PHARMA AG
  • BIOCHAIN-GENOMICS
  • BIOSTORAGE TECHNOLOGIES, INC.
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB CO
  • CANCER GENETICS
  • DAIICHI SANKYO COMPANY, LTD
  • ELI LILLY AND COMPANY
  • EXIQON LIFE SCIENCES
  • F. HOFFMAN-LA ROCHE AG
  • GLAXOSMITHKLINE
  • JOHNSON & JOHNSON LTD
  • MERCK & CO.
  • MILLENNIUM PHARMACEUTICALS
  • NOVARTIS AG
  • PFIZER INC
  • SANOFI-AVENTIS
  • SCIPAC
  • TAKEDA PHARMACEUTICALS LTD
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

List of Tables

  • TABLE # 1 GLOBAL BIOBANKING MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY, 2017-2023 ($ MILLIONS)
  • TABLE # 2 GLOBAL BIOBANKING MARKET RESEARCH AND ANALYSIS, BY SAMPLE TYPE, 2017-2023 ($ MILLIONS)
  • TABLE # 3 GLOBAL BLOOD PRODUCTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLIONS)
  • TABLE # 4 GLOBAL HUMAN TISSUES MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 5 GLOBAL NUCLEIC ACID MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 6 GLOBAL BIOLOGICAL FLUID MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 7 GLOBAL HUMAN WASTE PRODUCT MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 8 GLOBAL BIOBANKING MARKET RESEARCH AND ANALYSIS, BY APPLICATION, 2017-2023, ($ MILLIONS)
  • TABLE # 9 GLOBAL CLINICAL RESEARCH MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 10 GLOBAL REGENERATIVE MEDICINE MARKET RESEARCH AND ANALYSIS, 2017-2023, ($ MILLIONS)
  • TABLE # 11 NORTH AMERICAN BIOBANKING MARKET RESEARCH AND ANALYSIS, BY SAMPLE TYPE, 2017-2023, ($ MILLIONS)
  • TABLE # 12 NORTH AMERICAN BIOBANKING MARKET RESEARCH AND ANALYSIS, BY APPLICATION, 2017-2023, ($ MILLIONS)
  • TABLE # 13 EUROPEAN BIOBANKING MARKET RESEARCH AND ANALYSIS, BY SAMPLE TYPE, 2017-2023, ($ MILLIONS)
  • TABLE # 14 EUROPEAN BIOBANKING MARKET RESEARCH AND ANALYSIS, BY APPLICATION, 2017-2023, ($ MILLIONS)
  • TABLE # 15 APAC MARKET RESEARCH AND ANALYSIS, BY SAMPLE TYPE, 2017-2023, ($ MILLIONS)
  • TABLE # 16 APAC BIOBANKING MARKET RESEARCH AND ANALYSIS, BY APPLICATION, 2017-2023, ($ MILLIONS)

List of Figures

  • FIGURE # 1 GLOBAL BIOBANKING MARKET SHARE, BY SAMPLE TYPE, 2017 VS 2023, (%)
  • FIGURE # 2 GLOBAL BIOBANKING MARKET SHARE, BY APPLICATION, 2017 VS 2023, (%)
  • FIGURE # 3 NORTH AMERICAN BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 4 US BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 5 CANADA BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 6 EUROPEAN BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 7 UK BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 8 FRANCE BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 9 GERMANY BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 10 ITALY BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 11 SPAIN BIOBANKING MARKET SIZE, 2017 AND 2023, ($ MILLIONS)
  • FIGURE # 12 ROE BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 13 ASIA PACIFIC BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 14 INDIA BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 15 CHINA BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 16 JAPAN BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 17 ROAPAC BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
  • FIGURE # 18 REST OF THE WORLD BIOBANKING MARKET SIZE, 2017-2023, ($ MILLIONS)
目次
Product Code: OMR2018265

Global Biobanking market is expected to grow at a CAGR of 7.2% during 2018-2023. A biobank is a biorepository that is used to store biological samples of human to be used in research. Most of the bio-banked samples are used by research groups for the development of new tests and effective treatment of cancer. The growth of the market has been propelled by cohesive government policies and funding from government and private ventures in biobanks. Large biobanks were supported by government and charitable organizations while private funding maintains the pharmaceutical biobanks. For an instance, in the US, Cancer Human Biobank, Bethesda, MD (the caHUB) was developed and supported by the National Cancer Institute (NCI) for the preservation of high-quality human cancer tissue samples for medical research.

Moreover, the other factors contributing to the growth of the market include development in genomic research and other research programs such as clinical proteomics tumor analysis consortium. Additionally, increasing demand for cost-effective drug discovery, and advancement in biobanking are contributing significantly into the growth of the market. However, issues regarding biospecimen sample procurement and strict regulatory framework may affect the growth of the global biobanking market.

Geographically, the global biobanking market has been divided into North America, Europe, Asia Pacific and Rest of the World. North America has been predicted to dominate the global bio banking market owing to increasing research in cell and gene therapy, and regenerative medicine. The companies contributing to the growth of global biobanking market are Abbott Laboratories, Bayer Schering Pharma AG, Cancer genetics, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd., Merck & Company, Inc., Novartis AG, and Pfizer Inc. Majority of the biobanking market players have focus on various strategies such as acquisition or entering into strategic alliance with other major players to stay competitive and enhance their presence. Recently in March, 2017, UK biobank has taken an initiative with GSK and the Regeneron Genetics Center (RGC). Such strategies provides valuable insights to the researchers supporting the advancements in the development of new medicines for life threatening diseases.

Market Segmentation:

  • 1. Global biobanking market by sample type
  • 2. Global biobanking market by application

THE REPORT COVERS:

  • Comprehensive research methodology of Global Biobanking Market.
  • This report also includes detailed and extensive market overview with Analyst insights & key market trends.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global Biobanking Market.
  • Insights about market determinants which are stimulating the Global Biobanking Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

CHAPTER 1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

CHAPTER 2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
    • 2.3.1. UNITED STATES
    • 2.3.2. EUROPEAN UNION
    • 2.3.3. CHINA
    • 2.3.4. INDIA
    • 2.3.5. REST OF THE WORLD
  • 2.4. PIPELINE ANALYSIS

CHAPTER 3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. COHESIVE GOVERNMENT POLICIES
    • 3.1.2. HIGH INCIDENCE AND PREVALENCE OF CHRONIC DISEASES
    • 3.1.3. DEVELOPMENT IN GENOMICS RESEARCH
    • 3.1.4. RISING DEMAND FOR COST EFFICIENT DRUG DISCOVERY
    • 3.1.5. ADVANCEMENT IN BIOBANKING
  • 3.2. RESTRAINTS
    • 3.2.1. REGULATORY FRAMEWORK
    • 3.2.2. HIGH COST OF AUTOMATION IN BIOBANKING
    • 3.2.3. ISSUES REGARDING BIOSPECIMEN SAMPLE PROCUREMENT
  • 3.3. OPPORTUNITIES
    • 3.3.1. RISING HEREDITARY DISORDER
    • 3.3.2. INCREASING R&D OF CELL THERAPIES
    • 3.3.3. GROWING GOVERNMENT FUNDING IN BIOMEDICAL AND BIOTECHNOLOGY INDUSTRIES
    • 3.3.4. INCREASING PUBLIC/PRIVATE PARTNERSHIP

CHAPTER 4. MARKET SEGMENTATION

  • 4.1. GLOBAL BIOBANKING MARKET BY SAMPLE TYPE
    • 4.1.1. BLOOD PRODUCTS
    • 4.1.2. HUMAN TISSUES
    • 4.1.3. NUCLEIC ACID
    • 4.1.4. BIOLOGICAL FLUID
    • 4.1.5. HUMAN WASTE PRODUCT
  • 4.2. GLOBAL BIOBANKING MARKET BY APPLICATION
    • 4.2.1. CLINICAL RESEARCH
    • 4.2.2. REGENERATIVE MEDICINE

CHAPTER 5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS

CHAPTER 6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD

CHAPTER 7. COMPANY PROFILES

  • 7.1. ABBOTT LABORATORIES INC
  • 7.2. AFFYMETRIX, INC
  • 7.3. ASTERAND PLC
  • 7.4. ASTRAZENECA LTD
  • 7.5. BAYER SCHERING PHARMA AG
  • 7.6. BIOCHAIN-GENOMICS
  • 7.7. BIOSTORAGE TECHNOLOGIES, INC.
  • 7.8. BOEHRINGER INGELHEIM GMBH
  • 7.9. BRISTOL-MYERS SQUIBB CO
  • 7.10. CANCER GENETICS
  • 7.11. DAIICHI SANKYO COMPANY, LTD
  • 7.12. ELI LILLY AND COMPANY
  • 7.13. EXIQON LIFE SCIENCES
  • 7.14. F. HOFFMAN-LA ROCHE AG
  • 7.15. GLAXOSMITHKLINE
  • 7.16. JOHNSON & JOHNSON LTD
  • 7.17. MERCK & CO.
  • 7.18. MILLENNIUM PHARMACEUTICALS
  • 7.19. NOVARTIS AG
  • 7.20. PFIZER INC
  • 7.21. SANOFI-AVENTIS
  • 7.22. SCIPAC
  • 7.23. TAKEDA PHARMACEUTICALS LTD
  • 7.24. TEVA PHARMACEUTICAL INDUSTRIES LTD.
Back to Top